Almirall S.A., a global biopharmaceutical company focused on medical dermatology, entered into an agreement with Centrient Pharmaceuticals, a global business-to-business pioneer in sustainable, biosynthetic pharmaceutical products, including antibiotics, next-generation statins, and anti-fungals, to open its new dedicated innovation lab at Almirall’s R&D center in Barcelona. Centrient’s new Innovation Laboratory will start operations in the first quarter of 2024. The center serve...